AnaptysBio, Inc. Aktie News

SAN DIEGO, 21. Sept. 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), ein Unternehmen, das sich auf die Verwaltung der finanziellen Kooperationen für Jemperli mit Tesaro, einem Unternehmen von GSK, und Quimilza (imsidolimab) mit Vanda konzentriert, meldete heute die Finanzergebnisse für das zweite Quartal und das überleitende Geschäftsjahr zum 30. Juni 2026 und gab ein Unternehmensupdate.

SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.

SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced the appointment of Christopher Murphy as Chief Financial Officer and Owen Hughes as a member of its Board of Directors.

SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced that Daniel Faga, president and chief executive officer of Anaptys, is scheduled to participate in a fireside chat at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference on Wednesda...

WASHINGTON, April 28, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the publication of the original research article titled "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in New England Journal of Medicine (NEJM) Evidence1. The findings of this pivotal phase III study are included in the Biologics License Application (BLA) for im...

GSK PLC's (LSE:GSK, NYSE:GSK) oncology subsidiary TESARO has secured a partial legal victory after a Delaware court dismissed a counterclaim brought by AnaptysBio, the US biotechnology company, in a dispute over the licence for cancer drug dostarlimab. The Delaware Chancery Court granted TESARO's motion to dismiss AnaptysBio's claim for anticipatory breach, though the ruling does not address th...

SAN DIEGO, April 24, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced that the Delaware Chancery Court has dismissed Tesaro's anticipatory breach of contract claim against Anaptys. The ruling agrees with Anaptys' position that it has never repudiated the Collabor...

SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a royalty management company, today announced the completion of its spin-off of First Tracks Biotherapeutics, Inc., its former biopharma operations business.